To compare two different routes of intermittently administered rhIL-2 with a highly active antiretroviral regimen to highly active antiretroviral therapy alone with respect ot the proportion of subjects achieving 50% increase in CD4 counts above prerandomization baseline values after one year of rhIL-2 and the rate of change in CD4 counts. To compare the safety tolerance and effect on quality of life of these regimens. To assess the effects of rhIL-2 with highly active antiretroviral therapy on changes in immune cell phenotypes and function and on HIV viral load and rate of antiviral drung resistance development.
Showing the most recent 10 out of 497 publications